SCHEMBL6133505

SCHEMBL6133505

COc1ccc(CC(=O)c2ccccc2OC)nn1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.50
CTSD P07339 1/20 0.46
RAB9A P51151 1/20 0.46
ALDH1A1 P00352 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
CTNNB1 P35222 3/20 0.45
WNT3A P56704 3/20 0.45
IDO1 P14902 1/20 0.45
TDO2 P48775 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC1 Q13547 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 2/20 0.43
KDM4E B2RXH2 1/20 0.41
NNMT P40261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6133746 0.85 NPC1 (0.44) NPC1RAB9AALDH1A1L3MBTL1KMT2A
SCHEMBL6134086 0.84 ALDH1A1 (0.41) NPC1RAB9AALDH1A1L3MBTL1KMT2A
SCHEMBL6134151 0.80 NNMT (0.45) NPC1RAB9AALDH1A1L3MBTL1HTT
SCHEMBL5799347 0.76 NPC1 (0.48) NPC1RAB9AALDH1A1L3MBTL1HTT
SCHEMBL6133689 0.75 PDE4D (0.54) NPC1ALDH1A1HTTKMT2ACTNNB1
SCHEMBL6134262 0.75 NNMT (0.42) NPC1RAB9AALDH1A1HTTKMT2A
SCHEMBL6134635 0.75 SMN1; SMN2 (0.44) ALDH1A1KMT2ASMN1; SMN2LMNAKDM4E
SCHEMBL6134928 0.75 NNMT (0.42) NPC1RAB9AKMT2ASMN1; SMN2NNMT
SCHEMBL332837 0.74 TTR (0.66) NPC1CTSDALDH1A1L3MBTL1HTT
SCHEMBL29861033 0.74 NPC1 (0.63) NPC1CTSDRAB9AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ASTELLAS PHARMA INC. (JP) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ADORA2B, ADORA2A, ADORA1 NPC1 4182/4885CTSD 4663/4885RAB9A 1824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.